文献速递肺栓塞与肺血管病

丝裂霉素C诱导的肺静脉闭塞病:特征与长期结局

Characteristics and Long-term Outcomes of Pulmonary Venoocclusive Disease Induced by Mitomycin C.
PubMed 文献 · Chest · 2020-09-24

基于法国肺动脉高压注册登记,2011年6月至2018年12月共识别17例丝裂霉素C诱导的肺静脉闭塞病(PVOD)患者,诊断时临床与功能损害严重,停用丝裂霉素C并接受肺动脉高压靶向治疗后仅轻度改善,中位总生存期20个月。

要点

  • 丝裂霉素C暴露后PVOD虽罕见但致命,预后差。
  • 诊断时多存在严重功能受限与重度毛细血管前性肺动脉高压。
  • 停药及PAH靶向治疗改善有限,部分患者出现肺水肿需调整治疗。

核心结论

  • 丝裂霉素C治疗后发生的PVOD是一种罕见但威胁生命的并发症,尽管停用丝裂霉素C并给予PAH特异性治疗,预后仍差。

研究设计与样本

  • 基于法国肺动脉高压注册登记,纳入2011年6月至2018年12月暴露于丝裂霉素C后确诊PVOD的17例新发患者,报告诊断时临床、功能、影像及血流动力学特征与结局,结果以中位数(最小值-最大值)表示。

主要发现

  • 诊断时12例NYHA功能分级为III或IV级,6分钟步行距离为220(0-465)m。
  • 右心导管证实重度毛细血管前性肺动脉高压:平均肺动脉压38(30-52)mm Hg,心脏指数2.2(1.5-4)L/(min×m2),肺血管阻力8.3(5.1-14.5)Wood单位。
  • 一氧化碳弥散量为理论值的31%(20%-51%),并伴严重低氧血症。
  • 3例发生肺水肿需停用或减量PAH治疗;中位总生存期20个月,6、12、24个月生存率分别为76%、58%、18%。

临床怎么用

  • 对丝裂霉素C暴露后出现呼吸困难、低氧血症及弥散功能显著下降者,应警惕PVOD并及时行右心导管评估。
  • 确诊后应停用丝裂霉素C,PAH靶向治疗需谨慎,密切监测肺水肿并及时调整治疗。

局限性

  • 为注册登记描述性研究,样本量小(17例),未设对照,再评估为自身前后比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pulmonary venoocclusive disease (PVOD) is an uncommon form of pulmonary hypertension (PH) predominantly characterized by pulmonary vein and capillary involvement. An association between chemotherapy, in particular mitomycin C (MMC), and PVOD has been reported. RESEARCH QUESTION: What are the characteristics of MMC-induced PVOD, and what is the prognosis for patients with MMC-induced PVOD? STUDY DESIGN AND METHODS: We report the clinical, functional, radiologic, and hemodynamic characteristics at diagnosis and outcomes of patients with PVOD from the French PH Registry after exposure to MMC. The results are expressed as the median (minimum-maximum). RESULTS: From June 2011 to December 2018, 17 incident cases of MMC-induced PVOD were identified. At diagnosis, these patients had severe clinical and functional impairment, with 12 patients having a New York Heart Association (NYHA) functional class of III or IV and a 6-min walk distance of 220 (0-465) m. Right heart catheterization confirmed severe precapillary PH with a mean pulmonary artery pressure of 38 (30-52) mm Hg, a cardiac index of 2.2 (1.5-4) L/(min × m2), and pulmonary vascular resistance of 8.3 (5.1-14.5) Wood units. The diffusing capacity of the lungs for carbon monoxide was markedly decreased at 31% (20%-51%) of the theoretical values associated with severe hypoxemia. MMC was withdrawn for all patients, and 14 patients received specific pulmonary arterial hypertension (PAH) therapies. Among these patients, mild but statistically insignificant improvements were observed in NYHA functional class (P = .10), 6-min walk distance (P = .09), and pulmonary vascular resistance (-4.7 Wood units; P = .052) at reassessment (median delay of 4.8 months). Three patients experienced pulmonary edema requiring the cessation or reduction of PAH treatment. The median overall survival was 20 months, and the 6-, 12-, and 24-month survival rates were 76%, 58%, and 18%, respectively. INTERPRETATION: PVOD after MMC treatment is a rare but life-threatening complication associated with a poor prognosis despite MMC withdrawal and PAH-specific therapy.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Certain MC, Chaumais MC, Jaïs X, et al. Characteristics and Long-term Outcomes of Pulmonary Venoocclusive Disease Induced by Mitomycin C. Chest. 2020. PMID: 32979348. doi:10.1016/j.chest.2020.09.238

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。